Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

被引：0
|
作者：
Matthias Lang
Thomas Longerich
Chrysanthi Anamaterou
机构：
[1] University Hospital Heidelberg,Department of General
[2] University Hospital Heidelberg,, Visceral
[3] University of Heidelberg, and Transplant Surgery
来源：
Thyroid Research | / 16卷
关键词：
Anaplastic thyroid carcinoma; Vemurafenib; BRAF-inhibitor; Adjuvant targeted therapy; BRAF(V600E)-mutation; Review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
    Lang, Matthias
    Longerich, Thomas
    Anamaterou, Chrysanthi
    THYROID RESEARCH, 2023, 16 (01)
  • [2] BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
    Del Bufalo, Francesca
    Ceglie, Giulia
    Cacchione, Antonella
    Alessi, Iside
    Colafati, Giovanna Stefania
    Carai, Andrea
    Diomedi-Camassei, Francesca
    De Billy, Emmanuel
    Agolini, Emanuele
    Mastronuzzi, Angela
    Locatelli, Franco
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [3] Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib
    Marks, Asher M.
    Bindra, Ranjit S.
    DiLuna, Michael L.
    Huttner, Anita
    Jairam, Vikram
    Kahle, Kristopher T.
    Kieran, Mark W.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (05)
  • [4] Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
    Ali, Siraj M.
    He, Je
    Carson, Wade
    Stephens, Phil J.
    Fiorillo, Joseph
    Lipson, Doron
    Palmer, Gary A.
    Ross, Jeffrey S.
    Miller, Vincent A.
    Sharman, Jeffrey
    CASE REPORTS IN ONCOLOGY, 2014, 7 (02): : 343 - 348
  • [5] Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib
    van Tilburg, Cornelis M.
    Selt, Florian
    Sahm, Felix
    Baechli, Heidi
    Pfister, Stefan M.
    Witt, Olaf
    Milde, Till
    PEDIATRIC BLOOD & CANCER, 2018, 65 (03)
  • [6] Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib
    Follows, George A.
    Sims, Hannah
    Bloxham, David M.
    Zenz, Thorsten
    Hopper, Melanie A.
    Liu, Hongxiang
    Bench, Anthony
    Wright, Penny
    van't Veer, Mars B.
    Scott, Mike A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (01) : 150 - 153
  • [7] Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation
    Combe, Pierre
    Chauvenet, Laure
    Lefrere-Belda, Marie-Aude
    Blons, Helene
    Rousseau, Caroline
    Oudard, Stephane
    Pujade-Lauraine, Eric
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) : 1267 - 1270
  • [8] Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation
    Pierre Combe
    Laure Chauvenet
    Marie-Aude Lefrère-Belda
    Hélène Blons
    Caroline Rousseau
    Stéphane Oudard
    Eric Pujade-Lauraine
    Investigational New Drugs, 2015, 33 : 1267 - 1270
  • [9] BRAF V600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
    Ehlers, Margret
    Schmidt, Mathias
    Mattes-Gyorgy, Katalin
    Antke, Christina
    Enczmann, Juergen
    Schlensog, Martin
    Japp, Anna
    Haase, Matthias
    Allelein, Stephanie
    Dringenberg, Till
    Giesel, Frederik
    Esposito, Irene
    Schott, Matthias
    HORMONE AND METABOLIC RESEARCH, 2022, 54 (12) : 852 - 858
  • [10] Vemurafenib in Patients With BRAF V600E Mutation-Positive Advanced Melanoma
    Ravnan, Marcus C.
    Matalka, Mazen S.
    CLINICAL THERAPEUTICS, 2012, 34 (07) : 1474 - 1486
12345